Search Results

You are looking at 61 - 70 of 420 items for :

  • "single agent" x
Clear All
Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian and Anita Engh

CheckMate 067 showed that nivolumab (monotherapy) improved response rate and PFS compared with single-agent ipilimumab, and was associated with lower toxicity. 4 The results of CheckMate 066 and 067 demonstrated that, in the first-line setting, nivolumab

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Cristina Gasparetto, Francisco Hernandez-Illizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Michael Liedtke, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Furhan Yunus, Dorothy A. Shead and Rashmi Kumar

results of the open-label, single-arm phase II study in which 266 patients received single-agent carfilzomib intravenously twice weekly for 3 of 4 weeks. 6 Of the evaluable patients in this study, 95% were refractory to their last therapy, and 80% were

Full access

of enzalutamide and standard intravenous carboplatin and paclitaxel. Patients on the phase II portion of study (Part B) will undergo induction treatment with single-agent enzalutamide at 160 mg daily orally for 28 days (Cycle 0). Biopsies will be

Full access

mutation or are never-smokers generally do not benefit from single-agent immunotherapy. Subgroup analyses from the recent phase III IMpower150 trial suggested that immunotherapy-chemotherapy with vascular endothelial growth factor inhibition may overcome

Full access

of enzalutamide and standard intravenous carboplatin and paclitaxel. Patients on the phase II portion of study (Part B) will undergo induction treatment with single-agent enzalutamide at 160 mg daily orally for 28 days (cycle 0). Biopsies will be

Full access

IHC must demonstrate nonamplification (ratio <2) by standard in situ hybridization techniques (chromogenic in situ hybridization or fluorescence in situ hybridization). Primary Objectives: Determine if single-agent mirvetuximab induces response in at

Full access

Angela Jain, Paula D. Ryan and Michael V. Seiden

(FOLFIRI) and cetuximab was initiated but discontinued secondary to a hypersensitivity reaction with the first cycle. Single-agent trastuzumab was started, and over 3 weekly doses the patient’s CEA trended from 499 to 871, then 664. Restaging CT scan at

Full access

(chromogenic or fluorescence). Primary Objectives: Determine if single-agent mirvetuximab induces response with at least a 20% response rate per RECIST criteria in metastatic TNBC Determine if single-agent mirvetuximab in the neoadjuvant setting

Full access

patients with platinum-resistant, recurrent ovarian, fallopian tube, or primary peritoneal cancer, referred to collectively as ovarian cancer Secondary Objective: Determine the potential survival advantage and characterize the safety of single-agent

Full access

therapy. Recommended regimens for first-line therapy include cisplatin and pemetrexed (category 1 recommendation). Other regimens for first-line therapy are pemetrexed and carboplatin, gemcitabine and cisplatin, pemetrexed as a single agent, and